ANI Pharmaceuticals Inc.
| NASDAQ: ANIP |
| Healthcare / Drug Manufacturers / USA |
| 31.95 | +0.1500 | +0.47% | Vol 84.37K | 1Y Perf 17.27% |
| Sep 24th, 2021 16:00 DELAYED |
| BID | 31.94 | ASK | 32.00 | ||
| Open | 31.36 | Previous Close | 31.80 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 45.00 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 40.85 | Finscreener Ranking | ★★★+ 50.97 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★ 51.89 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★+ 42.40 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 51.06 | Earnings Rating | Strong Sell | |
| Market Cap | 407.75M | Earnings Date | 4th Nov 2021 | |
| Alpha | -0.02 | Standard Deviation | 0.12 | |
| Beta | 1.26 |
Today's Price Range 30.7132.17 | 52W Range 23.5540.00 | 5 Year PE Ratio Range -410.20213.40 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 10.59% | ||
| 1 Month | 13.82% | ||
| 3 Months | -3.30% | ||
| 6 Months | 1.72% | ||
| 1 Year | 17.27% | ||
| 3 Years | -40.08% | ||
| 5 Years | -52.06% | ||
| 10 Years | -63.78% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 0.37 | |||
ROE last 12 Months | -8.75 | |||
ROA (5Y Avg) | 0.15 | |||
ROA last 12 Months | -3.55 | |||
ROC (5Y Avg) | 2.60 | |||
ROC last 12 Months | -2.25 | |||
Return on invested Capital Q | -3.10 | |||
Return on invested Capital Y | -3.68 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -20.30 | ||||
| 1.92 | ||||
| 1.75 | ||||
| 25.60 | ||||
| -21.60 | ||||
| 1.13 | ||||
| 45.27 | ||||
| 15.05 | ||||
| 549.15M | ||||
| Forward PE | 9.11 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 2.10 | ||||
| 0.50 | ||||
| 1.07 | ||||
| -1.00 | ||||
| Leverage Ratio | 2.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 59.30 | ||||
| -4.80 | ||||
| 16.00 | ||||
| 3.00 | ||||
| -7.90 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 213.38M | ||||
| 16.73 | ||||
| 2.60 | ||||
| 13.57 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | 0.51 | 0.49 | -3.92 |
| Q01 2021 | 0.58 | 0.92 | 58.62 |
| Q04 2020 | 0.85 | 0.65 | -23.53 |
| Q03 2020 | 0.78 | 0.81 | 3.85 |
| Q02 2020 | 0.57 | 0.55 | -3.51 |
| Q01 2020 | 0.76 | 0.89 | 17.11 |
| Q04 2019 | 1.02 | 0.93 | -8.82 |
| Q03 2019 | 1.32 | 1.07 | -18.94 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2021 QR | 0.55 | -21.43 | Negative |
| 12/2021 QR | 0.83 | 3.75 | Positive |
| 12/2021 FY | 2.77 | 1.84 | Positive |
| 12/2022 FY | 3.17 | -12.43 | Negative |
| Next Report Date | 4th Nov 2021 |
| Estimated EPS Next Report | 0.55 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 84.37K |
| Shares Outstanding | 12.76M |
| Shares Float | 8.30M |
| Trades Count | 1.68K |
| Dollar Volume | 1.97M |
| Avg. Volume | 58.74K |
| Avg. Weekly Volume | 49.36K |
| Avg. Monthly Volume | 63.43K |
| Avg. Quarterly Volume | 61.31K |
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 31.95 per share at the end of the most recent trading day (a 0.47% change compared to the prior day closing price) with a volume of 87.98K shares and market capitalization of 407.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.
The one-year performance of ANI Pharmaceuticals Inc. stock is 17.27%, while year-to-date (YTD) performance is 10.02%. ANIP stock has a five-year performance of -52.06%. Its 52-week range is between 23.55 and 40, which gives ANIP stock a 52-week price range ratio of 51.06%
ANI Pharmaceuticals Inc. currently has a PE ratio of -20.30, a price-to-book (PB) ratio of 1.92, a price-to-sale (PS) ratio of 1.75, a price to cashflow ratio of 25.60, a PEG ratio of 2.32, a ROA of -3.55%, a ROC of -2.25% and a ROE of -8.75%. The company’s profit margin is -7.90%, its EBITDA margin is 16.00%, and its revenue ttm is $213.38 Million , which makes it $16.73 revenue per share.
Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $45, which is +40.85% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ANI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.66, ATR14 : 1.38, CCI20 : 150.74, Chaikin Money Flow : 0.26, MACD : 0.20, Money Flow Index : 78.99, ROC : 13.30, RSI : 63.07, STOCH (14,3) : 96.07, STOCH RSI : 1.00, UO : 68.34, Williams %R : -3.93), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Patrick D. Walsh (Buy at a value of $261 355)
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.
CEO: Nikhil Lalwani
Telephone: +1 218 634-3500
Address: 210 Main Street West, Baudette 56623, MN, US
Number of employees: 338
